inolimomab
PreclinicalMonoclonal antibody
inolimomab is one of 7 biologic programs targeting Acute Graft Versus Host Disease. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Acute Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Stelara
Johnson & JohnsonPhase 2
Arava
SanofiPhase 1
Gecacitinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
MC0518
Mmedac GmbH
Phase 2
inolimomab
EElsaLys Biotech
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for inolimomab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Preclinical[1]
- Company
- EElsaLys Biotech